SCHEMBL229061

SCHEMBL229061

COc1cc(NCCCc2ccc(CCN3C4CCC3CC4)cc2)c([C@@H]2CCc3cc(O)ccc3C2)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.45
ESR2 Q92731 2/20 0.45
GRIN2B Q13224 3/20 0.39
DRD2 P14416 1/20 0.38
DRD1 P21728 1/20 0.38
CYP26A1 O43174 1/20 0.37
CA9 Q16790 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SIGMAR1 Q99720 1/20 0.35
GRIN1 Q05586 1/20 0.35
CNR2 P34972 1/20 0.34
DHCR7 Q9UBM7 1/20 0.33
NR1I2 O75469 1/20 0.33
MAOA P21397 1/20 0.33
PTGS2 P35354 1/20 0.33
OPRK1 P41145 1/20 0.33
SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL228699 0.92 ESR1 (0.45) ESR1ESR2GRIN2BDRD2DRD1
SCHEMBL227143 0.92 ESR1 (0.45) ESR1ESR2GRIN2BDRD2DRD1
SCHEMBL228076 0.90 ESR1 (0.53) ESR1ESR2GRIN2BDRD2CYP26A1
SCHEMBL227039 0.89 ESR1 (0.45) ESR1ESR2GRIN2BDRD2DRD1
SCHEMBL228655 0.88 ESR1 (0.44) ESR1ESR2GRIN2BDRD2DRD1
SCHEMBL225838 0.88 ESR1 (0.44) ESR1ESR2GRIN2BDRD2DRD1
SCHEMBL229394 0.88 ESR1 (0.44) ESR1ESR2GRIN2BDRD2DRD1
SCHEMBL230138 0.88 ESR1 (0.44) ESR1ESR2GRIN2BDRD2DRD1
SCHEMBL228584 0.88 ESR1 (0.39) ESR1ESR2GRIN2BDRD2DRD1
SCHEMBL229635 0.88 ESR1 (0.39) ESR1ESR2GRIN2BDRD2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399520-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-03-19 US disclosed
US-20120004315-A1 Selective Estrogen Receptor Modulator RADIUS HEALTH, INC. 2012-01-05 US disclosed
US-7960412-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-06-14 US disclosed
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR RADIUS HEALTH, INC. 2009-12-31 US disclosed
US-7612114-B2 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI CO., LTD. (JP) 2006-06-01 US disclosed
EP-1577288-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS Eisai Co., Ltd. (JP) 2005-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR ESR1, GPER1, ESR2 ESR1 1/4885ESR2 3/4885GRIN2B 1206/4885
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer BRCA1, BCR, RCC1 ESR1 34/4885ESR2 21/4885GRIN2B 3266/4885
US-20120004315-A1 Selective Estrogen Receptor Modulator ESR1, GPER1, ESR2 ESR1 1/4885ESR2 3/4885GRIN2B 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.